Abstract: A vibration device includes a bimorph type piezoelectric element having a first main surface and a second main surface facing each other and a vibration member bonded to the second main surface of the piezoelectric element. The piezoelectric element has a first active region disposed closer to the first main surface between the first and second main surfaces and a second active region disposed closer to the second main surface than the first active region between the first and second main surfaces. When a force generated in the first active region is F1, a force generated in the second active region is F2, and a force by which the vibration member restrains the second active region is Fr, F2?F1?Fr is satisfied.

Abstract: A piezoelectric element includes a piezoelectric body, an electrode layer, and a reinforcing layer. The piezoelectric body has a first main surface, a second main surface, and a side surface. The first main surface and the second main surface oppose each other. The side surface extends in an opposing direction in which the first main surface and the second main surface oppose each other in such a way as to connect the first main surface and the second main surface. The electrode layer is provided in the piezoelectric body. The reinforcing layer is provided on the first main surface. The electrode layer is provided opposing the first main surface and apart from the side surface. When viewed from the opposing direction, the electrode layer has a corner. When viewed from the opposing direction, the reinforcing layer overlaps the corner.

Abstract: Provided is a combination drug. The present invention provides a pharmaceutical agent comprising (1) a HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) not less than one pharmaceutical agent selected from an mTOR inhibitor, a PI3 kinase inhibitor and a cMet inhibitor in combination.

Abstract: The present invention provides a method for treating cancer, which includes selecting a patient coexpressing HER2 and HER3, and administering an effective amount of a HER2 inhibitor to the patient.

Abstract: The present invention provides an agent for preventing or treating a trastuzumab-resistant cancer, which contains one or more medicaments selected from a cofilin inhibitor, a PAK1 inhibitor, a LIMK inhibitor, a RHO inhibitor, a ROCK1 inhibitor and a ROCK2 inhibitor.

Abstract: The present invention provides a pharmaceutical agent containing an HER2 inhibitor and a hormonal therapeutic agent or anti-cancer agent in combination. The present invention provides a pharmaceutical agent containing (1) an HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) a hormonal therapeutic agent or an anti-cancer agent in combination.

Abstract: The present invention provides a method for treating cancer, which includes selecting a patient coexpressing HER2 and HER3, and administering an effective amount of a HER2 inhibitor to the patient.

Abstract: A starting clutch control device includes a starting clutch disposed between an engine and a transmission installed to a vehicle. A torque coefficient setting section sets a torque coefficient based on a clutch speed ratio of the starting clutch and a throttle opening of the engine. A torque coefficient correction section increases the torque coefficient by a torque coefficient correction amount, increasing the torque coefficient by a progressively larger torque coefficient correction amount as the throttle opening increases, in order to increase the torque coefficient within a region of smaller clutch speed ratios (e.g., clutch speed ratios less than approximately 0.5). A hydraulic pressure control section controls hydraulic pressure supplied to the starting clutch based on the torque coefficient and the rotational speed of the engine.

Abstract: An ac generator for a vehicle is constituted so that the thickness in insulation layers of conductors in the slot-in portions located in the slot is smaller than the other to permit a metal portion of conductors to be much larger and to increase a density of conductors in the slots, causing heating from electrical conductors to efficiently conduct to a laminated core and a housing. On the contrary, the thickness in insulating layers of the cross-over portions is larger than the other to assure insulation capability among the coils and to prevent conductors of the cross-over portion axially exposed from the core to air from water immersion to improve an electrolytic corrosion resistibility without disposing unnecessary space among coils.

Abstract: A starting clutch control device includes a starting clutch disposed between an engine and a transmission installed to a vehicle. A torque coefficient setting section sets a torque coefficient based on a clutch speed ratio of the starting clutch and a throttle opening of the engine. A torque coefficient correction section increases the torque coefficient by a torque coefficient correction amount, increasing the torque coefficient by a progressively larger torque coefficient correction amount as the throttle opening increases, in order to increase the torque coefficient within a region of smaller clutch speed ratios (e.g., clutch speed ratios less than approximately 0.5). A hydraulic pressure control section controls hydraulic pressure supplied to the starting clutch based on the torque coefficient and the rotational speed of the engine.

Abstract: This invention relates to a compound of the following formula or a salt thereof, their production and use. ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; R.sup.3 represents hydrogen, halogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; W represents an oxygen atom or sulfur atom; A represents a group forming a nitrogen-containing condensed ring at the 3,4- of a 1,4-thiazine ring; R.sup.1 and R.sup.2 may be combined to form a bivalent hydrocarbon group interrupted by one or more hetero atoms or an alkylene group.